Its clinic activity against NSCLC is being tested in combination with DNA methyltransferase (DNMT) inhibitor Azacitidine or EGFR inhibitor Erlotinib (Tarceva), but not conventional chemotherapy (http://www.clinicaltrial.gov/ct2/results?term=entinostat&Search=Search). This evidence concerns the gene DNMT1 and non-small cell lung carcinoma.